Golidocitinib Combined With Selinexor for CAEBVD

Key facts

Sponsor

Beijing Friendship Hospital

Intervention

golidocitinib(drug)

Enrollment

28 target

Eligibility

18-70 years · All sexes

Timeline

2026 – 2028

Study locations (1)

• Beijing Friendship Hospital, Beijing, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Anorectal malformation

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07441083
  Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness
  SF Research Institute, Inc.
• RECRUITINGPHASE1NCT07545967
  Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
  West China Hospital
• RECRUITINGNCT07438691
  Outcomes in ARMs: Comparison Between Surgical Techniques in Patients With Perineal or Vestibular Fistula - a Multicenter Italian Study
  Meyer Children's Hospital IRCCS
• RECRUITINGNCT07174388
  A Study in Non-Small Cell Lung Cancer
  N-Power Medicine
• RECRUITINGNANCT07366476
  Effectiveness of Electrical Stimulation and Biofeedback on Fecal Incontinence in Children With Repaired Anorectal Malformation
  Sinai University
• RECRUITINGPHASE2NCT07311577
  Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study
  Jiangsu Cancer Institute & Hospital
• RECRUITINGNANCT07263451
  Safety and Feasibility of IRE for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study
  Tian'an Jiang
• RECRUITINGPHASE2NCT07447570
  Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
  Second Affiliated Hospital, School of Medicine, Zhejiang University

See all trials for Anorectal malformation →